UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 18, 2023
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
Registrant’s Telephone Number, Including Area Code: ( | ||
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
The annual meeting of shareholders of Inari Medical, Inc. (the “Company”) was held on May 18, 2023. The final voting results for each proposal are set forth below.
1.Each of the following Class III director nominees was elected to serve on the Company’s board of directors for a three-year term expiring at the Company’s 2026 annual meeting of shareholders, by the following vote:
| Names of Nominee | Votes For | Votes Withheld | Broker Non-Votes | |||||||||||||||||
| Cynthia Lucchese | 35,340,330 | 10,698,171 | 5,311,980 | |||||||||||||||||
| Jonathan Root, M.D. | 32,079,459 | 13,959,042 | 5,311,980 | |||||||||||||||||
| Robert Warner | 45,664,293 | 383,013 | 5,303,175 | |||||||||||||||||
2.The shareholders ratified the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The votes regarding this proposal were as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||||||||
| 51,013,353 | 284,978 | 52,150 | 0 | |||||||||||||||||
3.The shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in our proxy statement. The votes regarding this proposal were as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||||||||
| 42,519,009 | 3,417,294 | 111,003 | 5,303,175 | |||||||||||||||||
No other matters were submitted for shareholder action.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INARI MEDICAL, INC. | |||||||||||
| Date: | May 19, 2023 | By: | /s/ Mitchell Hill | ||||||||
Mitchell Hill Chief Financial Officer | |||||||||||